Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System by Emanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, Elisabetta Poluzzi, Fabrizio De Ponti

Get full text

Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase^® Spontaneous Reporting System by Roberta Noseda, Laura Müller, Francesca Bedussi, Michele Fusaroli, Emanuel Raschi, Alessandro Ceschi

Get full text

Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions. by Marica Iommi, Simona Rosa, Michele Fusaroli, Paola Rucci, Maria Pia Fantini, Elisabetta Poluzzi

Get full text

Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal by Emanuel Raschi, Michele Fusaroli, Milo Gatti, Paolo Caraceni, Elisabetta Poluzzi, Fabrizio De Ponti

Get full text

Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People by Carlotta Lunghi, Caterina Trevisan, Michele Fusaroli, Valentina Giunchi, Emanuel Raschi, Elisa Sangiorgi, Marco Domenicali, Stefano Volpato, Fabrizio De Ponti, Elisabetta Poluzzi

Get full text

Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System by Emanuel Raschi, Michele Fusaroli, Valentina Giunchi, Andrea Repaci, Carla Pelusi, Veronica Mollica, Francesco Massari, Andrea Ardizzoni, Elisabetta Poluzzi, Uberto Pagotto, Guido Di Dalmazi

Get full text

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors by Monia Sisi, MD, Giovanni Vitale, MD, PhD, Michele Fusaroli, MD, Mattia Riefolo, MD, Valentina Giunchi, BSc, Antonietta D’Errico, MD, Andrea Ardizzoni, MD, Emanuel Raschi, MD, PhD, Francesco Gelsomino, MD

Get full text